Acrivon Therapeutics Inc ACRV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.74
- Day Range
- $1.73–1.78
- 52-Week Range
- $1.20–3.56
- Bid/Ask
- $1.70 / $1.78
- Shares Outstanding
- 42.80M
- Market Cap
- $74.90M
- Volume/Avg
- 124,129 / 557,980
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 76
- Website
- https://www.acrivon.com
Valuation
|
Metric
|
ACRV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACRV
|
|---|---|
Quick Ratio | 8.84 |
Current Ratio | 8.98 |
Interest Coverage | — |
Quick Ratio
ACRV
Profitability
|
Metric
|
ACRV
|
|---|---|
Return on Assets (Normalized) | −44.69% |
Return on Equity (Normalized) | −50.12% |
Return on Invested Capital (Normalized) | −53.16% |
Return on Assets
ACRV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x$^JgSh | LOCK|<@v<H | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R#X&^P$ | LOCK|TPmd | $71B | |||
| argenx SE ADR
ARGX
| LOCK|S#?tPs! | LOCK|hV | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r#@c<vv | LOCK|BZ | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d<&DP? | LOCK|Jg@l< | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|D^yb%R<& | LOCK|n!<n@ | $26B | |||
| Moderna Inc
MRNA
| LOCK|S#N%Mw | LOCK|Fw | $24B | |||
| Incyte Corp
INCY
| LOCK|L^^%G#g | LOCK|yBH | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#^##Y> | LOCK|KY@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Y>#m$r | LOCK|!p | $16B |
United States